Immunovant, Inc.
NASDAQImmunovant heads into the final weeks of September with an unusual tension: options traders are the most bullish they have been all year, yet short sellers have quietly been adding to positions over the past month. The options market is sending a strikingly one-sided signal. The put/call ratio dropped to 0.26 this week — nearly three standard deviations below its 20-day average of…
Snapshot as of 4 Oct 2026
Immunovant heads into the final weeks of September with an unusual tension: options traders are the most bullish they have been all year, yet short sellers have quietly been adding to positions over the past month. The…
Immunovant heads into its May 29 earnings event with the positioning picture reversed from a week ago — options traders have rotated from aggressive call buying to measurable put demand, even as the stock has surged…
Immunovant heads into its May 29 earnings event with one of the most polarised positioning setups in the biotech space — aggressive call buying on one side, stubborn short sellers and a parade of executive sales on the…
Immunovant is heading into its May 29 earnings event carrying a sharply split set of signals — an unusually bullish options print colliding with a stubborn double-digit short position and a month of executive…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IMVT — free to start on ORTEX.
Sign up for free →Open IMVT on ORTEX